MMP-9 Inhibitors

NNGH (CAS 161314-17-6) is a chemical compound that functions as an inhibitor of MMP-9, an enzyme involved in extracellular matrix remodeling. It modulates MMP-9 activity, impacting processes related to tissue integrity.

Chlorhexidine Dihydrochloride (CAS 3697-42-5) functions as an MMP-9 inhibitor, impacting enzymatic processes without clinical connotations.

MMP-2/MMP-9 Inhibitor I acts as a potent inhibitor of MMP-9, showcasing a unique binding affinity that disrupts the enzyme's catalytic activity. This compound engages in specific molecular interactions that stabilize the enzyme's inactive conformation, effectively blocking substrate binding. Its kinetic profile reveals a competitive inhibition mechanism, influencing the dynamics of matrix metalloproteinase activity and altering the balance of extracellular matrix turnover.

MMP-9/MMP-13 inhibitor I (CAS 204140-01-2) is a chemical compound known for its capacity to inhibit MMP-9. It interacts with the MMP-9 enzyme, modulating its activity. The compound's mechanism involves restraining MMP-9's function without delving into clinical applications.

CP 471474 functions as a selective inhibitor of MMP-9, characterized by its ability to form stable complexes with the enzyme. This compound exhibits unique interactions at the active site, preventing substrate access and altering the enzyme's conformational dynamics. Its reaction kinetics suggest a non-competitive inhibition model, which modifies the overall enzymatic activity and impacts the regulation of extracellular matrix remodeling processes.

Acts as a selective inhibitor of MMP-9, limiting its ability to degrade components of the extracellular matrix.

Cis-ACCP acts as a potent inhibitor of MMP-9, distinguished by its capacity to engage in specific hydrogen bonding and hydrophobic interactions with the enzyme's active site. This compound alters the enzyme's structural conformation, leading to a decrease in catalytic efficiency. Its unique binding affinity results in a distinct modulation of enzymatic pathways, influencing the turnover rates of substrates and the overall dynamics of matrix metalloproteinase activity.

ARP 101 functions as a selective inhibitor of MMP-9, characterized by its ability to form stable complexes through unique electrostatic interactions and van der Waals forces with the enzyme. This compound induces conformational changes that disrupt the enzyme's catalytic mechanism, effectively slowing substrate processing. Its distinct kinetic profile highlights a competitive inhibition pattern, altering the balance of extracellular matrix remodeling and influencing cellular signaling pathways.

MMP-9/MMP-13 Inhibitor II exhibits a remarkable capacity to modulate matrix metalloproteinase activity through specific binding interactions that stabilize the enzyme's inactive form. This compound engages in hydrogen bonding and hydrophobic interactions, leading to a significant alteration in the enzyme's active site conformation. Its unique reaction kinetics reveal a non-competitive inhibition mechanism, impacting the dynamics of tissue remodeling and cellular communication.

4-Aminobenzoyl-Gly-Pro-D-Leu-D-Ala hydroxamic acid (CAS 124168-73-6) is a compound known for its ability to inhibit MMP-9, an enzyme involved in extracellular matrix degradation. It modulates MMP-9 activity, impacting processes associated with tissue remodeling.